quality by design in pharmaceutical analysis to pharmaceutical analysis understanding the analytical...
Post on 30-Mar-2018
219 Views
Preview:
TRANSCRIPT
SPEAKERS:
Dr Joachim ErmerSanofi, Germany
Patrick JacksonGSK, United Kingdom
HIGHLIGHTS:
� Application of QbD and life cycle principles to pharmaceutical analysis
� Understanding the Analytical Target Profile (ATP)
� Decision rules and establishment of acceptance limits
� QbD-Method development � Traditional versus QbD Validation � Life-cycle and change management � Five hours of interactive workshops
1 – 2 October 2015, Budapest, Hungary
Quality by Design in Pharmaceutical Analysis
This education course is recognised for the ECA GMP Certification Programme „Certified Pharmaceutical Development Manager“. Please find details at www.gmp-certification.eu
� With practical oriented workshop case studies
Objectives
The aim of this two day course is to provide guidance on how QbD principles can be applied to analytical meth-ods and identify the opportunities, not only for new de-velopment products, but also for drugs already market-ed. This course will deal among others with the following questions:
� What are the opportunities of applying QbD and life cycle approach to analytical methods?
� What is the current status of analytical QbD (USP, FDA-EMA, FDA Draft Guidance Method Validation)?
� How can the Analytical Target Profile increase regulatory flexibility?
� Why is it important to have a clear understanding and expectation of method performance?
� What is the impact of QbD on method development, validation and transfer?
� What is the advantage of the 3-Stage lifecycle approach to validation?
� How can QbD also benefit marketed products?
A number of interactive workshops will be provided throughout the two days which will enable delegates to to apply what they have learnt and to discuss the con-cepts in more detail. Delegates will have the opportunity to work through the whole QbD process by gaining “hands-on experience” using a number of case studies.
Background
The pharmaceutical industry is currently embracing QbD concepts to help improve the robustness of manufactur-ing processes and to facilitate continuous improvement strategies to enhance product quality and manufacturing productivity. QbD ensures product and process perform-ance characteristics are scientifically designed to meet specific objectives, not merely empirically derived from the performance of test batches. Key QbD concepts are described in ICH guidelines Q8 (R1) Pharmaceutical Development, Q9 Quality Risk management and Q10 Pharmaceutical Quality System. The same opportunities exist for applying QbD to analytical methods as they do for manufacturing processes.
During the course an overview of a position paper written jointly by PhRMA and EFPIA and of a USP Stimuli Article will be provided which use a new concept called the Analytical Target Profile (ATP). It parallels the concept of a Quality Target Product Profile described and defined in ICH Q8 and defines the performance requirements for the measurement of a given Quality Attribute. The ATP will be used to drive all analytical life cycle activities within the three stages (Method Design, Method Perfor-mance Qualification, Continued Method Performance Verification) including change control.
It is hoped that greater continuous improvement of methods can also be facilitated if regulatory authorities agree with and approve the ATP statement. Each method conforming to the ATP requirements would be imple-mented by the company’s internal change control man-agement system, thus providing regulatory flexibility. Risk assessment tools and statistical methods used to facilitate understanding of the method performance characteris-tics (e.g. accuracy and precision) and their acceptance criteria will also be covered. Traditional method valida-tion will be compared to a QbD approach which in-cludes life-cycle aspects instead of a one off validation exercise.
Note: In order to fully benefit from the workshops, attendees should preferably bring a notebook with Excel®.
Target Audience
This course is designed for analytical managers and sci-entists who are responsible for performing or reviewing activities like method development, validation, transfer, operation and monitoring of methods in a QC environ-ment, statistical evaluation of method performance, ana-lytical change control etc.
In addition, QA and regulatory affairs professionals will benefit from this course by gaining an understanding in future CMC trends. This will aid more effective multifunc-tional discussions on these topics within industry.
Programme
Introduction to Analytical QbD � Overview on proposals of EFPIA/PhRMA Paper and
USP Stimuli Article � Analytical Target Profile � Application of QbD principles to pharmaceutical
analysis � Change Control and regulatory flexibility
Design Intent of the Method – ATP and Business Re-quirements
� Linkage with process control strategy (critical quality attributes)
� Definition of ATP � Method Performance Characteristics and their criteria � Business requirements of method
Understanding the ATP – Analytical Variability � Sources of analytical variability � Method performance characteristics: accuracy and
precision � Method performance and expectation ranges for
experimental results and statistical parameters � Decision rules and establishment of acceptance limits
Quality by Design in Pharmaceutical Analysis
1 – 2 October 2015, Budapest, Hungary
Workshop on Variability � Application of statistical simulations � Gain experience (“feeling”) for the consequences of
variability � Method performance statistical measures for
precision, accuracy, linearity � Probability of OOS and out-of acceptance criteria
situations
QbD Method Development � Method design � Method selection � Risk assessment � Control Definition of method (robustness and
ruggedness testing)
Workshop Risk Assessment � Use of fishbone diagrams � Identification of controllable factors, noise factors
and experimental parameters (CNX) � Use of priority matrix and failure mode and effects
analysis (FMEA)
Traditional Validation versus QbD Validation � “Translation” of ATP into specific method require-
ments � Identification of relevant performance parameters � Establishment of appropriate acceptance criteria � Life-cycle approach, continued performance
verification
Life-cycle and change management � Knowledge management system � Analytical Method Transfer � Routine method operation � Continuous method verification, change control and
regulatory implications
Workshop Case StudiesStarting from provided ATPs for several critical quality attributes, delegates will be split into small groups in order to discuss how each ATP is translated into meth-od specific performance characteristics and acceptance criteria. The impact of changing the method will be as-sessed for each ATP. Examples of Critical Quality attrib-utes will be used such as
� Identification of an API in a tablet formulation � Assay of drug substance � Water content in drug substance � Determination of degradants in drug product
Wrap up & Final DiscussionThe concepts and tools used over the two days will be summarised and future implications and opportunities of applying QbD principles to analytical measurements will be discussed. Delegates will be given time to ask ques-tions on how they can apply what they have learnt to their own analytical methods.
Speakers
DR JOACHIM ERMERHead of Quality Control Services Chemis-try, Sanofi-Aventis Deutschland GmbH, Frankfurt, Germany. He studied biochemis-try at University of Halle and has over 20 years experience in pharmaceutical analyt-ics including development products, glob-
al responsibilities as Director of Analytical Processes and Technology, and Head of Quality Control. He is member of the EFPIA QbD working group and of the USP Expert Panel Validation & Verification.
DR PATRICK JACKSONPatrick Jackson is an analyst at GSK leading analytical quality by design application within Product Development, Stevenage, UK with more than 8 years experience in the pharmaceutical industry working on Active Pharmaceutical Ingredients and
chemical route development. Pat studied at York Univer-sity where he obtained a Masters in Chemistry and later obtained a Masters in Applied Statistics from Sheffield Hallam University. Pat is also an associate member of The Royal Society of Chemistry.
Social Event
On 1 October 2015, you are cordially invited to a social event. This is an excellent opportunity to share your experiences with colleagues from other companies in a relaxed atmosphere.
Rese
rvat
ion
Form
(Ple
ase
com
ple
te in
full)
Qu
alit
y b
y D
esig
n in
Ph
arm
aceu
tica
l An
alys
is1 –
2 O
cto
ber
20
15, B
udap
est,
Hun
gary
*
Mr
*M
s
Title
, firs
t nam
e, s
urna
me
Co
mp
any
Dep
artm
ent
Imp
ort
ant:
Ple
ase
ind
icat
e yo
ur c
om
pan
y’s
VA
T ID
Nu
mb
er
PO N
um
ber
if a
pp
licab
le
Stre
et/P
.O. B
ox
City
Z
ip C
od
e C
oun
try
Pho
ne
Fax
E-M
ail (
ple
ase
fill i
n)
1 – 2 October 2015, Budapest, Hungary
If th
e b
ill-t
o-a
dd
ress
dev
iate
s fr
om
the
spec
ifica
tions
on
the
right
, p
leas
e fil
l out
her
e:
C
ON
CEP
T H
EID
ELBE
RG
P.O
. Box
1017
64
Fax
+49
(0) 6
2 21
/84
44 3
4
D
-690
07
Hei
del
ber
g
GER
MA
NY
+
49
6221
84
44 3
4 Easy Registration
Reservation Form:CONCEPT HEIDELBERGP.O. Box 10 17 6469007 HeidelbergGermany
Reservation Form:+ 49 6221 84 44 34 @ e-mail:
info@concept-heidelberg.de Internet:www.gmp-compliance.org
wa/vers1/09102014
Date
Thursday, 1 October 2015, 9.00 h – 18.15 h(Registration and coffee 8.30 h – 9.00 h)Friday, 2 October 2015, 9.00 h – 15.30 h
Venue
Hilton Budapest WestEndVáci út 1-31062 Budapest, HungaryPhone +36 1 288 5500Fax +36 1 288 5588 Fees (per delegate plus VAT)
ECA Members € 1,590APIC Members € 1,690Non-ECA Members € 1,790EU GMP Inspectorates € 895The conference fee is payable in advance after re-ceipt of invoice and includes conference docu-mentation, dinner on the first day, lunch on both days and all refreshments. VAT is reclaimable.
Accommodation
CONCEPT HEIDELBERG has reserved a limited number of rooms in the conference hotel. You will receive a room reservation form when you have registered for the course. Reservation should be made directly with the hotel. Early reservation is recommended.
Registration
Via the attached reservation form, by e-mail or by fax message. Or you register online at www.gmp-compliance.org.
Conference Language
The official conference language will be English.
Organisation and Contact
ECA has entrusted Concept Heidelberg with the organisation of this event.
CONCEPT HEIDELBERGP.O. Box 10 17 64 69007 HeidelbergGermanyPhone ++49-62 21/84 44-0 Fax ++49-62 21/84 44 84info@concept-heidelberg.dewww.concept-heidelberg.de
For questions regarding content:Dr Gerhard Becker (Operations Director) at +49-62 21/84 44 65, or per e-mail at becker@concept-heidelberg.de.
For questions regarding reservation, hotel, organisation etc.:Susanne Ludwig (Organisation Manager) at +49-62 21/84 44 44, or per e-mail at ludwig@concept-heidelberg.de
Gen
eral
term
s an
d c
ond
itio
nsIf
you
cann
ot a
ttend
the
conf
eren
ce y
ou h
ave
two
optio
ns:
1. W
e ar
e ha
ppy
to w
elco
me
a su
bst
itute
col
leag
ue a
t any
tim
e.2.
If y
ou h
ave
to c
ance
l ent
irely
we
mus
t cha
rge
the
follo
win
g pr
oces
sing
fees
: Can
cella
tion
- un
til 2
wee
ks p
rior t
o th
e co
nfer
ence
10 %
,-
until
1 w
eeks
prio
r to
the
conf
eren
ce 5
0 %
- w
ithin
1 w
eek
prio
r to
the
conf
eren
ce 10
0 %
.C
ON
CEP
T H
EID
ELBE
RG re
serv
es th
e rig
ht to
cha
nge
the
mat
eria
ls, i
n-
stru
ctor
s, o
r spe
aker
s w
ithou
t not
ice
or to
can
cel a
n ev
ent.
If th
e ev
ent
mus
t be
canc
elle
d, r
egis
tran
ts w
ill b
e no
tified
as
soon
as
poss
ible
and
w
ill re
ceiv
e a
full
refu
nd o
f fee
s p
aid
. CO
NC
EPT
HEI
DEL
BERG
will
not
b
e re
spon
sib
le fo
r dis
coun
t airf
are
pena
lties
or o
ther
cos
ts in
curr
ed
due
to a
can
cella
tion.
Te
rms
of p
aym
ent:
Pay
able
with
out d
educ
-tio
ns w
ithin
10 d
ays
afte
r rec
eip
t of i
nvoi
ce.
Imp
ort
ant:
Thi
s is
a b
ind
ing
regi
stra
tion
and
ab
ove
fees
are
due
in
case
of c
ance
llatio
n or
non
-ap
pea
ranc
e. If
you
can
not t
ake
part
,
you
have
to in
form
us
in w
ritin
g. T
he c
ance
llatio
n fe
e w
ill th
en b
e ca
lcul
ated
acc
ord
ing
to th
e po
int o
f tim
e at
whi
ch w
e re
ceiv
e yo
ur
mes
sage
. In
case
you
do
not a
ppea
r at t
he e
vent
with
out h
avin
g in
form
ed u
s, y
ou w
ill h
ave
to p
ay th
e fu
ll re
gist
ratio
n fe
e, e
ven
if yo
u ha
ve n
ot m
ade
the
paym
ent y
et. O
nly
afte
r we
have
rece
ived
yo
ur p
aym
ent,
you
are
entit
led
to p
artic
ipat
e in
the
conf
eren
ce
(rec
eipt
of p
aym
ent w
ill n
ot b
e co
nfirm
ed)!
(As
of Ja
nuar
y 20
12)
Priv
acy
Polic
y: B
y re
gist
erin
g fo
r thi
s ev
ent,
I acc
ept t
he p
roce
ssin
g of
my
Pers
onal
Dat
a. C
once
pt H
eid
elb
erg
will
use
my
dat
a fo
r the
pr
oces
sing
of t
his
ord
er, f
or w
hich
I he
reb
y d
ecla
re to
agr
ee th
at m
y pe
rson
al d
ata
is s
tore
d a
nd p
roce
ssed
. Con
cept
Hei
del
ber
g w
ill o
nly
send
me
info
rmat
ion
in re
latio
n w
ith th
is o
rder
or s
imila
r one
s. M
y pe
rson
al d
ata
will
not
be
dis
clos
ed to
third
par
ties
(see
als
o th
e pr
i-va
cy p
olic
y at
http
://w
ww
.gm
p-co
mpl
ianc
e.or
g/ec
a_pr
ivac
y.ht
ml).
I n
ote
that
I ca
n as
k fo
r the
mod
ifica
tion,
cor
rect
ion
or d
elet
ion
of m
y d
ata
at a
ny ti
me
via
the
cont
act f
orm
on
this
web
site
.
#
top related